Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.49 |
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853287 | 0.86 | LPAR1 (0.58) | KDM4ELPAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL13695133 | 0.86 | PKM (0.59) | KDM4ELPAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL2386068 | 0.86 | KMT2A (0.73) | HSD17B10ALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL27754464 | 0.85 | LPAR1 (0.60) | KDM4ELPAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL10624511 | 0.84 | ALDH1A1 (0.78) | KDM4ELPAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL9994970 | 0.83 | KDM4E (0.55) | KDM4EHSD17B10LPAR1ALDH1A1HSD17B1 | |
| SCHEMBL1504060 | 0.83 | LPAR1 (0.56) | KDM4ELPAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL25210284 | 0.83 | ALDH1A1 (0.51) | LPAR1ALDH1A1MEN1KMT2AEPHX1 | |
| SCHEMBL9400208 | 0.82 | HSD17B1 (0.77) | KDM4EHSD17B10ALDH1A1HSD17B1HSD17B2 | |
| SCHEMBL22158983 | 0.82 | RORC (0.56) | KDM4EHSD17B10LPAR1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020141439-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-09 | — | — | WO | disclosed |
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | KDM4E 936/4885HSD17B10 108/4885LPAR1 4740/4885 |
| US-20070060569-A1 | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | MMP9, MMP1, MMP13 | KDM4E 1602/4885HSD17B10 330/4885LPAR1 494/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | KDM4E 1406/4885HSD17B10 2543/4885LPAR1 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.